Key facts
- It has raised $4.7M; the latest was Seed Round ($4.7M) in Apr 2026.
- Notable investors include Mizuho Capital, One Capital (Tokyo), LINK-J, Saisei Ventures.
- Status: Privately Held (backing).
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for Senno Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Senno Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Senno Therapeutics
Developer of biotechnology intended to create innovative treatments that save patients. The company offers innovative cell therapy products developed from human induced pluripotent stem cell-derived hepatic progenitor cells and liver organoid technologies to treat fatal liver failure, enabling healthcare professionals to provide life-saving, minimally invasive alternatives to organ transplantation, giving patients access to cures without depending on scarce donor organs.
- Sector
- Healthcare
- HQ
- Tokyo, Japan
- Founded
- 2020
- Website
- sennotx.com/
- Ownership
- Privately Held (backing)
Senno Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Senno Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Senno Therapeutics in its N-PORT filings yet. We sweep new filings monthly.